Flucelvax Pregnancy Registry
Flucelvax Pregnancy Registry: an Observational Study on the Safety of Flucelvax Exposure in Pregnant Women and Their Offspring
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28401
- PPD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnancy women pregnant women aged 18 years or older within the US who were immunized with the Flucelvax vaccine at any time during pregnancy.The registry will allow eligible pregnant women to selfenroll and also allow HCPs to report de-identified data on pregnancy exposures and outcomes.
- Sufficient evidence to confirm that Flucelvax exposure occurred during pregnancy
- Sufficient information to determine whether the pregnancy is prospectively or retrospectively registered (ie, whether the outcome of pregnancy was known at the time of first contact with the registry)
- Date the pregnancy exposure is registered
- Full reporter (ie, HCP) contact information to allow for follow-up (name, address,etc) The primary population for analysis will include prospectively enrolled pregnancies exposed to Flucelvax that are not lost to follow-up (ie, with outcome information that meet the minimum criteria for evaluation)
Exclusion Criteria:
- Invalid registry reports and pregnancies deemed lost to follow-up will be excluded from the primary analysis. Retrospective reports will not be included, although retrospective cases with MCMs will be reviewed and reported separately.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1, Flucelvax
Flucelvax exposure in pregnancy
|
vaccine exposure in routine care (no vaccination per protocol)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
major congenital malformation
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
|
preterm birth
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
|
low birth weight
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Live birth
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
|
stillbirth
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
|
spontaneous abortion
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
|
ectopic pregnancy
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
|
molar pregnancy
Time Frame: From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
From time of enrollment during pregnancy to time of delivery or pregnancy termination
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- V58_36OB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnant Women, Influenza
-
NCT07540130Active, not recruitingPregnant Women | Pregnant Women and Their Offspring
-
NCT07372313Not yet recruitingHypotension in Pregnant Women | Headache in Pregnant Women
-
NCT07258329Recruiting
-
NCT07199140Not yet recruiting
-
NCT06001905Recruiting
-
NCT05358834Recruiting
-
NCT05335330Recruiting
Clinical Trials on Flucelvax (cTIV)
-
NCT00511914Completed
-
NCT03438487CompletedPregnancy | Influenza, Human | Birth Defect
-
NCT02967393Completed
-
NCT03743688CompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1
-
NCT04025580Completed